Premium
Gadobenate dimeglumine–enhanced magnetic resonance imaging of primary leiomyoma of the liver
Author(s) -
Marin Daniele,
Catalano Carlo,
Rossi Massimo,
Guerrisi Antonino,
Di Martino Michele,
Berloco Pasquale,
Passariello Roberto
Publication year - 2008
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.21519
Subject(s) - medicine , magnetic resonance imaging , gadoxetic acid , leiomyoma , radiology , lesion , malignancy , nuclear medicine , liver tumor , pathology , hepatocellular carcinoma , gadolinium dtpa
We report a case of histologically proven primary leiomyoma of the liver that was evaluated with multiphasic 64‐section computed tomography (CT) and gadobenate dimeglumine–enhanced magnetic resonance (MR) imaging. This lesion showed vivid enhancement during the arterial phase with sustained enhancement during the hepatic venous and equilibrium phases. During the liver‐specific MR imaging phase (150 minutes after contrast injection), the same lesion demonstrated lack of contrast retention, thus appearing hypointense compared with the background liver. Because of this latter finding, the patient underwent partial resection of the liver. In primary hepatic leiomyoma, the absence of contrast uptake during the liver‐specific phase of gadobenate dimeglumine–enhanced MR imaging may be inappropriately interpreted as a sign of malignancy, thus leading to unnecessary, aggressive management of such lesions. J. Magn. Reson. Imaging 2008;28:755–758. © 2008 Wiley‐Liss, Inc.